Abstracts tagged "anti-TNF therapy"

Abstract Number: 1520 • 2015 ACR/ARHP Annual Meeting
Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Jeffrey R. Curtis^1,2, Anita Turner³, Corretta Thomas⁴, Stacey Cofield⁴, Randall Parks⁵, Jennifer H. Ku⁶, Ilhem Messaoudi- Powers⁷, Keith Wanzeck¹ and Kevin L. Winthrop⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama-Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: The live herpes zoster vaccine (ZV) has been shown to be safe and effective in large randomized controlled trials of older adults. It is…
Abstract Number: 2603 • 2015 ACR/ARHP Annual Meeting
What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?
Regan Arendse¹, Boulos Haraoui², Denis Choquette³, John Kelsall⁴, Philip Baer⁵, Dalton Sholter⁶, William G. Bensen⁷, Mary J. Bell⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Cathy Tkaczyk¹², Karina Maslova¹³, Francois Nantel¹⁴ and Allen J Lehman¹³, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheum Div, Sunnybrook Health Sciences Centre/University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : The Health Assessment Questionnaire (HAQ) remains the gold standard for measuring patient-reported functional status in rheumatoid arthritis (RA) and is included among the…
Abstract Number: 2870 • 2015 ACR/ARHP Annual Meeting
Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Michel Zummer¹, Proton Rahman², Regan Arendse³, Michael Starr⁴, John Kelsall⁵, J Antonio Avina-Zubieta⁶, Philip Baer⁷, Dalton Sholter⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Karina Maslova¹³, Francois Nantel¹⁴, Allen J Lehman¹³ and Cathy Tkaczyk¹², ¹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸Rheumatology Associates, Edmonton, AB, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current analysis…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 1636 • 2015 ACR/ARHP Annual Meeting
Clinical Benefit of 1-Year Certolizumab Pegol Treatment in MTX-Naïve, Early Rheumatoid Arthritis Patients Is Maintained after Discontinuation up to 1 Year
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike¹⁵, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc., Japan, Tokyo, Japan, ¹³University Hospital, Maastricht, Netherlands, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Efficacy and safety of certolizumab pegol (CZP) treatment in combination with optimized-dose MTX in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with poor…
Abstract Number: 2694 • 2015 ACR/ARHP Annual Meeting
Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis
Zuzana Tatar¹, Carole Migne², Mélanie Petera³, Estelle Pujos Guillot⁴, Philippe Gaudin^5,6, T Lequerré⁷, Hubert Marotte⁸, Jacques Tebib⁹ and Martin Soubrier¹, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Metabolomic Plateform INRA, Theix-Clermont-Ferrand, France, ³Metabolomic Plateform, INRA, Theix -Clermont-Ferrand, France, ⁴Metabolomic Plateform, INRA, Theix-Clermont-Ferrand, France, ⁵Rheumatology, University Hospital, Grenoble, France, ⁶Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁷Rheumatology Department and INSERM U 905, CHU Hôpitaux de Rouen, Rouen, France, ⁸INSERM 1059 / LBTO, Université de Lyon, Saint-Etienne; Rheumatology Department, Saint-Etienne, France, ⁹Rheumatology Department, Centre Hospitalier Lyon-Sud, Pierre-Bénite Lyon, France
Background/Purpose: Anti-TNF-alpha therapies are able to control rheumatoid arthritis (RA) disease activity and to limit structural damage. Nevertheless, no predictive factor of response to anti-TNF-alpha,…
Abstract Number: 2871 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Denis Choquette¹, Proton Rahman², Maqbool Sheriff³, Wojciech Olszynski⁴, Emmanouil Rampakakis⁵, Eliofotisti Psaradellis⁶, Francois Nantel⁷, Brendan Osborne⁸, Allen J Lehman⁹, Karina Maslova⁹ and Cathy Tkaczyk⁸, ¹Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵JSS Medical Research, St-Laurent, QC, Canada, ⁶JSS Medical Research, Montreal, QC, Canada, ⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ⁸Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Although the efficacy and tolerability of golimumab (GLM) in patients with ankylosing spondylitis (AS) has been demonstrated in several controlled clinical trials, it is…
Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting
Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Ulla Vogel⁴, Steffen Bank^5,6, Paal Skytt Andersen⁷, Merete Lund Hetland^8,9, Henning Locht³, Niels H. H. Heegaard^10,11 and Vibeke Andersen^1,5,12,13, ¹Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ²Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark, ⁵Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ¹¹Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, ¹²Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹³Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies
Ronald van Vollenhoven¹, S. B. Cohen², Philip J. Mease³, Charles G. Peterfy⁴, Wolfgang Spieler⁵, Judith Boice⁶, Sean Curtis⁷, Qing Li⁷, Ruji Yao⁸, Richard Baumgartner⁷ and Holly Weng⁸, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Washington, Seattle, WA, ⁴Spire Sciences LLC, Boca Raton, FL, ⁵Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁶Merck Research Laboratories, Whitehouse Station, NJ, ⁷Merck & Co., Inc, Whitehouse Station, NJ, ⁸Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA). MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…
Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Jürgen Braun¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Owen Davies⁵, Tommi Nurminen⁴ and Desiree van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
Abstract Number: 2495 • 2014 ACR/ARHP Annual Meeting
Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Chenglong Han¹, Edward C. Keystone², Roy Fleischmann³, Josef Smolen⁴, Eric L. Matteson⁵, Paul Emery⁶, Mark C Genovese⁷, Timothy A. Gathany¹ and Elizabeth C. Hsia^8,9, ¹Janssen Global Services, LLC., Malvern, PA, ²University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ³Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ⁴Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after…
Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Anaïz Nutz¹, Yohan Duny², Thomas Barnetche³, Jacques Morel⁴, Bernard Combe⁵ and Claire Daien⁶, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²INSERM, Montpellier, France, ³Department of rheumatology, Bordeau, France, ⁴Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Philip J. Mease¹, Roy Fleischmann², Jurgen Wollenhaupt³, Atul A. Deodhar⁴, Dafna D. Gladman⁵, Bengt Hoepken⁶, Luke Peterson⁷ and Désirée M. van der Heijde⁸, ¹Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Oregon Health and Sciences University, Portland, OR, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶UCB Pharma, Monheim, Germany, ⁷Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
Abstract Number: 2475 • 2014 ACR/ARHP Annual Meeting
Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Edward C. Keystone¹, Josef Smolen², Vibeke Strand³, Thomas Kumke⁴, Irina Mountian⁵, Susan Walker⁶ and Robert B. M. Landewé^7,8, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴UCB Pharma, Monheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands
Background/Purpose Use of imputed or observed data, as well as the patient (pt) population evaluated (eg. intention-to-treat [ITT], completer), affects the interpretation of long-term efficacy…
Abstract Number: 1472 • 2014 ACR/ARHP Annual Meeting
Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes
Maria Sole Chimenti, Alberto Bergamini, Eleonora Baffari, Eleonora Ballanti, Alessia Musto, Paola Conigliaro and Roberto Perricone, Rheumatology, allergology and clinical immunology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy
Background/Purpose Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by infiltration of the synovium by inflammatory cells that destroys the cartilage and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].